Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study
RC48 plus PD-1 inhibitor for pre-treated advanced G/GEJC patients with HER2 2+/3+ demonstrated superior efficacy than RC48 monotherapy and favourable safety. This combination represents a potential therapeutic strategy, but further large-scale prospective studies are still needed.
Authors
- Fengping Li (ORCID: https://orcid.org/0000-0002-8535-112X)
- Ming-Yu Lai
- Min Lai
- Tsao‐Cheng Huang (ORCID: https://orcid.org/0000-0002-8294-4149)
- Zhiwei Li (ORCID: https://orcid.org/0000-0002-2870-7265)
- Kaobin Ouyang
- Huayuan Liang
- Miao‐Zhen Qiu (ORCID: https://orcid.org/0000-0002-4774-6235)
- Rou Zhong
- Zhong Xie (ORCID: https://orcid.org/0000-0002-4669-5923)
- Liying Zhao
- Kaihua Huang
- Qing Xie
- Li Yang (ORCID: https://orcid.org/0009-0004-7545-8726)
- Yan Xiao (ORCID: https://orcid.org/0009-0009-5758-2578)
- Huimin Zhang (ORCID: https://orcid.org/0000-0002-8584-4311)
Institutions
- Sun Yat-sen University (CN)
- Guangdong Medical College (CN)
- Nanfang Hospital (CN)
- Huizhou Central People's Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Affiliated Hospital of Guangdong Medical College Hospital (CN)
- State Key Laboratory of Oncology in South China
- Southern Medical University (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-10-11
- DOI
- https://doi.org/10.1080/07853890.2025.2569994
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.04